Sofosbuvir and ribavirin with or without pegylated-interferon in hepatitis C virus genotype-2 or -3 infections: A systematic review and meta-analysis

peer reviewedBackground: Direct-acting antiviral agents (DAAs) have changed the treatment landscape of hepatitis C virus (HCV) infection. Sofosbuvir (SOF), as a DAA inhibiting HCV NS5B polymerase, has found a remarkable contribution to the treatment regimens of HCV genotype-2 (HCV-2) and -3 infections. Objectives: In this meta-analysis, we aimed to evaluate the efficacy of the combination of SOF and Ribavirin (RBV) with or without pegylated-interferon (PegIFN) in the treatment of HCV-2 and -3 infections. Methods: In this meta-analysis, we searched electronic databases including PubMed, Scopus, ScienceDirect, andWeb of Science using appropriate and relevant keywords. Based on the results of the heterogeneity test (chi-squared and I-squared), fixed- or randomeffects models were used to calculate the pooled sustained virological response (SVR) rates. Results: After removing duplicates and screening of 1408 articles, 16 studies were included in the quantitative synthesis. The pooled SVR rates calculated for the treatment of patients suffering HCV-2 infection were 92% (95% CI: 87% - 96%) using the SOF + RBV regimen for 12 weeks and 95% (95% CI: 85% - 100%) using the SOF + RBV + PegIFN regimen for 12 weeks. The pooled SVR calculated for the treatment of patients suffering HCV-3 infection was 55% (95% CI: 44% - 66%) using the SOF + RBV regimen for 12 weeks, 81% (95% CI: 72% - 88%) using the SOF + RBV regimen for 24 weeks, and 93% (95% CI: 85% - 99%) using the SOF + RBV + PegIFN regimen for 12 weeks. Conclusions: The combination of SOF and RBV with or without PegIFN for 12 weeks is highly efficacious (> 90%) for the treatment of patients with HCV-2 infection. However, for the treatment of patients with HCV-3 infection only 12 weeks of SOF + PegIFN + RBV would result in > 90% treatment success